12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lifitegrast: Phase III data

Top-line data from the double-blind, U.S. Phase III OPUS-1 trial in 588 patients with dry eye disease showed that twice-daily 5% lifitegrast met the co-primary endpoint of improving inferior corneal staining scores from baseline to week 12 vs. placebo (p=0.0007). Lifitegrast missed the co-primary endpoint of improving visual-related function score as measured by ODSI score vs. placebo (p=0.7894). On secondary endpoints, lifitegrast significantly improved total corneal staining (p=0.0148), mean ocular...

Read the full 328 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >